Trial · NCT00274716
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | mm Hg | MEAN |
| SECONDARY | Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | mm Hg | MEAN |
| SECONDARY | Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | kg | MEAN |
| SECONDARY | Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | cm | MEAN |
| SECONDARY | Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | percentage change | MEAN |
| SECONDARY | Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | Percent change | MEAN |
| SECONDARY | Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI) | Baseline and Week 12 (end of Phase A) | Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint. | Percent change | MEAN |
| PRIMARY | Number of Participants Who Reported a Clinical Adverse Event | 24 weeks | All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy. | Participants | NUMBER |
| PRIMARY | Number of Participants Who Reported a Laboratory Adverse Event | 24 weeks | All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy. | Participants | NUMBER |
| PRIMARY | Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event | 24 weeks | All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy. | Participants | NUMBER |
| PRIMARY | Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event | 24 weeks | All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy. | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00274716/outcomes